Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression

LI YAN

Status: Not yet enrolling

Conditions: Non-small Cell Lung Cancer

Treatments: Genetic: GSTP1 A313G （AA）

Study type: Observational

Funder types: Other

Identifiers

NCT06140082

QFS-LY-2022-GSTP1-001

Details and patient eligibility

About

This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.

Full description

Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. To study the risk factors related to myelosuppression during chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused by combination chemotherapy with platinum.

Enrollment: 477 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with non-small cell lung cancer with clear imaging or pathological evidence
2. Using a chemotherapy regimen containing platinum
3. Conducted blood routine and biochemical tests
4. Signed informed consent

Exclusion criteria

1. Blood routine and other relevant tests were not performed
2. Suffering from primary bone marrow system disease
3. Other reasons for not meeting the experimental requirements

Trial design

477 participants in 2 patient groups

Gene mutation-type group

Description:

According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected, genetic testing was performed, GSTP1 mutant (AG/GG) was classified into this group, and the time and degree of myelosuppression in this group were recorded.

Gene wild-type group

Description:

According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected for genetic testing, GSTP1 wild type (AA) was classified into this group, and the time and degree of myelosuppression in this group were recorded.

Treatment:

Genetic: GSTP1 A313G （AA）